Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT-523 in Refractory Leukemia
NCT00129558Phase 2Withdrawn
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Jul 2005
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talotrexin in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), sponsored by Spectrum Pharmaceuticals, Inc.. Planned start Jul 2005; status: withdrawn.
02
Drugs
talotrexin
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00129558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129558.